image
Blueprint Medicines Corporation BPMC
Healthcare - Biotechnology - NASDAQ - US
Watchlist
$ 81.68
-6.23 %
$ 5.22 B
Market Cap
-76.34
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Mar, 31, 2025.

The intrinsic value of one BPMC stock under the worst case scenario is HIDDEN Compared to the current market price of 81.7 USD, Blueprint Medicines Corporation is HIDDEN

BPMC Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Mar, 31, 2025.

The intrinsic value of one BPMC stock under the base case scenario is HIDDEN Compared to the current market price of 81.7 USD, Blueprint Medicines Corporation is HIDDEN

BPMC Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Mar, 31, 2025.

The intrinsic value of one BPMC stock under the best case scenario is HIDDEN Compared to the current market price of 81.7 USD, Blueprint Medicines Corporation is HIDDEN

BPMC Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart BPMC

image
1M -7.0%
6M -8%
1Y -12%
3Y 17%
5Y 22%
All
$120.0$120.0$115.0$115.0$110.0$110.0$105.0$105.0$100.0$100.0$95.0$95.0$90.0$90.0$85.0$85.0$80.0$80.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
509 M REVENUE
104.04%
Growth Rates
1Year 104.04%
3Years 41.37%
5Years 50.22%
7Years 57.22%
10Years 0.00%
-212 M OPERATING INCOME
56.39%
Growth Rates
1Year 56.39%
3Years 31.11%
5Years 10.37%
7Years -5.12%
10Years -18.20%
-67.1 M NET INCOME
86.77%
Growth Rates
1Year 86.77%
3Years 52.95%
5Years 28.04%
7Years 10.70%
10Years -5.23%
-193 M OPERATING CASH FLOW
55.91%
Growth Rates
1Year 55.91%
3Years 13.61%
5Years 7.08%
7Years -7.01%
10Years -18.46%
-47.5 M INVESTING CASH FLOW
-17.33%
Growth Rates
1Year -17.33%
3Years 40.53%
5Years -23.60%
7Years 6.47%
10Years -52.46%
273 M FINANCING CASH FLOW
129.07%
Growth Rates
1Year 129.07%
3Years 75.28%
5Years -4.32%
7Years -9.37%
10Years 12.87%
146 M REVENUE
14.18%
Growth Rates
1Year 104.04%
3Years 41.37%
5Years 50.22%
7Years 57.22%
10Years 0.00%
0 OPERATING INCOME
100.00%
Growth Rates
1Year 56.39%
3Years 31.11%
5Years 10.37%
7Years -5.12%
10Years -18.20%
-50 M NET INCOME
11.23%
Growth Rates
1Year 86.77%
3Years 52.95%
5Years 28.04%
7Years 10.70%
10Years -5.23%
-29.4 M OPERATING CASH FLOW
-115.33%
Growth Rates
1Year 55.91%
3Years 13.61%
5Years 7.08%
7Years -7.01%
10Years -18.46%
33.7 M INVESTING CASH FLOW
12.55%
Growth Rates
1Year -17.33%
3Years 40.53%
5Years -23.60%
7Years 6.47%
10Years -52.46%
9.76 M FINANCING CASH FLOW
-46.90%
Growth Rates
1Year 129.07%
3Years 75.28%
5Years -4.32%
7Years -9.37%
10Years 12.87%
Balance Sheet Blueprint Medicines Corporation
image
Current Assets 743 M
Cash & Short-Term Investments 615 M
Receivables 77.6 M
Other Current Assets 49.6 M
Non-Current Assets 437 M
Long-Term Investments 0
PP&E 101 M
Other Non-Current Assets 336 M
52.17 %6.58 %4.20 %8.54 %28.51 %Total Assets$1.2b
Current Liabilities 261 M
Accounts Payable 6.79 M
Short-Term Debt 57.3 M
Other Current Liabilities 197 M
Non-Current Liabilities 620 M
Long-Term Debt 68.8 M
Other Non-Current Liabilities 552 M
6.50 %22.33 %7.81 %62.60 %Total Liabilities$881.1m
EFFICIENCY
Earnings Waterfall Blueprint Medicines Corporation
image
Revenue 509 M
Cost Of Revenue 20.2 M
Gross Profit 489 M
Operating Expenses 701 M
Operating Income -212 M
Other Expenses -145 M
Net Income -67.1 M
600m600m500m500m400m400m300m300m200m200m100m100m00(100m)(100m)(200m)(200m)(300m)(300m)509m(20m)489m(701m)(212m)145m(67m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
96.04% GROSS MARGIN
96.04%
Averages
1Year 96.04%
3Years 94.06%
5Years 94.43%
7Years 17.85%
10Years -96.87%
-41.67% OPERATING MARGIN
-41.67%
Averages
1Year -41.67%
3Years -168.62%
5Years -165.58%
7Years -276.27%
10Years -336.17%
-13.19% NET MARGIN
-13.19%
Averages
1Year -13.19%
3Years -163.24%
5Years -161.57%
7Years -261.94%
10Years -324.88%
-22.46% ROE
-22.46%
Averages
1Year -22.46%
3Years -172.99%
5Years -112.79%
7Years -98.75%
10Years -78.56%
-5.69% ROA
-5.69%
Averages
1Year -5.69%
3Years -31.77%
5Years -25.69%
7Years -31.25%
10Years -29.46%
-22.12% ROIC
-22.12%
Averages
1Year -22.12%
3Years -40.59%
5Years -32.24%
7Years -38.76%
10Years -35.40%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Blueprint Medicines Corporation
image
400m400m300m300m200m200m100m100m00(100m)(100m)(200m)(200m)(300m)(300m)(400m)(400m)(500m)(500m)(600m)(600m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -67.1 M
Depreciation & Amortization -6.17 M
Capital Expenditures -4.63 M
Stock-Based Compensation 109 M
Change in Working Capital 0
Others -228 M
Free Cash Flow -197 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Blueprint Medicines Corporation
image
Wall Street analysts predict an average 1-year price target for BPMC of $122 , with forecasts ranging from a low of $88 to a high of $155 .
BPMC Lowest Price Target Wall Street Target
88 USD 7.74%
BPMC Average Price Target Wall Street Target
122 USD 49.85%
BPMC Highest Price Target Wall Street Target
155 USD 89.76%
Price
Max Price Target
Min Price Target
Average Price Target
16016015015014014013013012012011011010010090908080May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 10
6. Ownership
Insider Ownership Blueprint Medicines Corporation
image
Sold
0-3 MONTHS
10.1 M USD 11
3-6 MONTHS
4.56 M USD 5
6-9 MONTHS
7.75 M USD 5
9-12 MONTHS
15.1 M USD 5
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Blueprint Medicines Highlights Leading Portfolio of Mast Cell-Targeted Therapies at 2025 AAAAI / WAO Joint Congress -- Updated data show AYVAKIT® (avapritinib) was safe and effective for long-term treatment of ISM, with sustained symptom and quality-of-life benefit and no new safety signals with multiple years of therapy -- -- AYVAKIT-treated patients achieved improvements in bone health based on an analysis of bone mineral density scans, underscoring the importance of treating patients early in the ISM disease course --  -- BLU-808 healthy volunteer trial results demonstrate wide therapeutic window for modulating mast cell activity, affirming potential as best- and first-in-class oral wild-type KIT inhibitor -- CAMBRIDGE, Mass. , Feb. 28, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced data presentations reflecting its ongoing efforts to innovate the treatment of mast cell-driven diseases. prnewswire.com - 1 month ago
BPMC Q4 Earnings and Sales Miss Estimates, Shares Decline Blueprint Medicines' fourth-quarter earnings and sales miss estimates. Shares of the company decline following the announcement. zacks.com - 1 month ago
Blueprint Medicines Corporation (BPMC) Q4 2024 Earnings Call Transcript Blueprint Medicines Corporation (NASDAQ:BPMC ) Q4 2024 Earnings Conference Call February 13, 2025 8:00 AM ET Company Participants Cassie Saitow - Director, Investor Relations Kate Haviland - President and Chief Executive Officer Philina Lee - Chief Commercial Officer Becker Hewes - Chief Medical Officer Mike Landsittel - Chief Financial Officer Christina Rossi - Chief Operating Officer Conference Call Participants Brad Canino - Stifel Salveen Richter - Goldman Sachs Michael Schmidt - Guggenheim Brian Cheng - J.P. Morgan Derek Archila - Wells Fargo Marc Frahm - TD Cowen Laura Prendergast - Raymond James Michael Ulz - Morgan Stanley David Dai - UBS Reni Benjamin - Citizens JMP Colleen Kusy - Baird Matthew Biegler - Oppenheimer David Nierengarten - Wedbush Securities Operator Good morning. seekingalpha.com - 1 month ago
Blueprint Medicines (BPMC) Reports Q4 Loss, Misses Revenue Estimates Blueprint Medicines (BPMC) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of a loss of $0.70. This compares to loss of $1.82 per share a year ago. zacks.com - 1 month ago
Blueprint Medicines Reports Fourth Quarter and Full Year 2024 Results -- Achieved $479.0 million in AYVAKIT® (avapritinib) global net product revenues in 2024, including $144.1 million in the fourth quarter -- -- Anticipate global AYVAKIT net product revenue of approximately $680 million to $710 million in 2025, representing 45% percent year-over-year growth at the midpoint -- -- Peak systemic mastocytosis franchise revenue opportunity updated to $4 billion, with AYVAKIT expected to achieve $2 billion in revenue by 2030 -- -- AYVAKIT 3-year safety and efficacy results in ISM and BLU-808 healthy volunteer data among 14 total abstracts accepted for presentation at 2025 AAAAI / WAO Joint Congress -- CAMBRIDGE, Mass. , Feb. 13, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2024 and provided financial guidance. prnewswire.com - 1 month ago
Will Blueprint Medicines (BPMC) Report Negative Earnings Next Week? What You Should Know Blueprint Medicines (BPMC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com - 1 month ago
Should You Buy Blueprint Medicines (BPMC) After Golden Cross? After reaching an important support level, Blueprint Medicines Corporation (BPMC) could be a good stock pick from a technical perspective. BPMC recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average. zacks.com - 1 month ago
Blueprint Medicines to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025 CAMBRIDGE, Mass. , Feb. 5, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. prnewswire.com - 2 months ago
Blueprint Stock Soars 18% on Encouraging 2025 Growth Strategy BPMC stock rallies 18% on the company's optimistic 2025 outlook encompassing Ayvakit sales growth and pipeline progress. zacks.com - 2 months ago
5 Biotech Stocks Worth Adding to Your Portfolio in 2025 New drug approvals and pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry despite the uncertain macro environment. A strong portfolio and solid pipeline progress position INCY, BMRN, EXEL, HALO and BPMC well in this volatile sector. zacks.com - 2 months ago
Blueprint Medicines (BPMC) Stock Jumps 18.2%: Will It Continue to Soar? Blueprint Medicines (BPMC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. zacks.com - 2 months ago
Blueprint Medicines price target lowered by $11 at Wedbush, here's why Blueprint Medicines -3.19 (-3.52%) Celldex -2.21 (-8.33%) https://thefly.com - 2 months ago
8. Profile Summary

Blueprint Medicines Corporation BPMC

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 5.22 B
Dividend Yield 0.00%
Description Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Contact 45 Sidney Street, Cambridge, MA, 02139 https://www.blueprintmedicines.com
IPO Date April 30, 2015
Employees 649
Officers Mr. Michael Landsittel CPA Chief Financial Officer Dr. Percy H. Carter M.B.A., Ph.D. Chief Scientific Officer Ms. Tracey L. McCain Esq. Executive Vice President, Chief Legal & Compliance Officer and Secretary Ms. Kathryn Haviland M.B.A. President, Chief Executive Officer & Director Dr. Fouad Namouni M.D. President of Research & Development Ms. Jenna Cohen Senior Director & Head of Investor Relations Ms. Christina Rossi M.B.A. Chief Operating Officer Ms. Ariel Hurley Senior Vice President, Finance & Principal Accounting Officer Mr. Alexis A. Borisy A.M. Co-Founder & Director Ms. Debra Durso-Bumpus Chief People Officer